Pharmafile Logo

compulsory licence

National Institute for Health and Care Excellence NICE logo

NICE changes tack on Sanofi’s prostate cancer drug Jevtana

Approves the therapy for NHS use after accepting undisclosed additional discount 

Roche - Basel

Cancer drugs help Roche beat expectations in first quarter

Sales of Avastin and Herceptin show no sign of slowing down

Bristol Myers Squibb logo

Opdivo boosts survival in head and neck cancer by 30%

Pivotal trial of BMS’ PD-1 inhibitor shows "significant benefit" in overall survival

- PMLiVE

AbbVie and Roche to launch Venclexta within a week

FDA approves first-in-class BCL-2 inhibitor to treat chronic lymphocytic leukaemia patients

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo gets two new indications in Europe

Receives green light as lung and kidney cancer immunotherapy

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

- PMLiVE

India denies Vertex patent on cystic fibrosis drug Orkambi

Says treatment is neither innovative or more effective than its predecessor

Bristol Myers Squibb logo

Opdivo edges closer to first haematological cancer indication

EMA begins review of BMS' classic Hodgkin’s lymphoma inhibitor treatment

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

- PMLiVE

Roche integrates diabetes app with Apple Health

Accu-Chek Connect will allow patients to share data with the iPhone system

- PMLiVE

NICE promises UK to lead Europe for cancer drug approvals

But industry says running the new CDF will present NICE with a ‘hugely challenging’ task

- PMLiVE

BMS appoints Peter Arduini to board of directors

He brings experience from Integra LifeSciences and Baxter Healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links